Please use this identifier to cite or link to this item: https://swslhd.intersearch.com.au/swslhdjspui/handle/1/9644
Title: Treatment of Gestational Diabetes Mellitus Diagnosed Early in Pregnancy
Author: Simmons, D.
Immanuel, J.
Hague, W. M.
Teede, H.
Nolan, C. J.
Peek, M. J.
Flack, J. R.
McLean, M.
Wong, V.
Hibbert, E.
Kautzky-Willer, A.
Harreiter, J.
Backman, H.
Gianatti, E.
Sweeting, A.
Mohan, V.
Enticott, J.
Cheung, N. W.
SWSLHD Author: Flack, Jeffrey R.
Issue Date: 2023
Journal: New England Journal of Medicine
Abstract:  Background Whether treatment of gestational diabetes before 20 weeks' gestation improves maternal and infant health is unclear. Methods We randomly assigned, in a 1:1 ratio, women between 4 weeks' and 19 weeks 6 days' gestation who had a risk factor for hyperglycemia and a diagnosis of gestational diabetes (World Health Organization 2013 criteria) to receive immediate treatment for gestational diabetes or deferred or no treatment, depending on the results of a repeat oral glucose-tolerance test [OGTT] at 24 to 28 weeks' gestation (control). The trial included three primary outcomes: a composite of adverse neonatal outcomes (birth at <37 weeks' gestation, birth trauma, birth weight of �4500 g, respiratory distress, phototherapy, stillbirth or neonatal death, or shoulder dystocia), pregnancy-related hypertension (preeclampsia, eclampsia, or gestational hypertension), and neonatal lean body mass. Results A total of 802 women underwent randomization; 406 were assigned to the immediate-treatment group and 396 to the control group; follow-up data were available for 793 women (98.9%). An initial OGTT was performed at a mean (�SD) gestation of 15.6�2.5 weeks. An adverse neonatal outcome event occurred in 94 of 378 women (24.9%) in the immediate-treatment group and in 113 of 370 women (30.5%) in the control group (adjusted risk difference, -5.6 percentage points; 95% confidence interval [CI], -10.1 to -1.2). Pregnancy-related hypertension occurred in 40 of 378 women (10.6%) in the immediate-treatment group and in 37 of 372 women (9.9%) in the control group (adjusted risk difference, 0.7 percentage points; 95% CI, -1.6 to 2.9). The mean neonatal lean body mass was 2.86 kg in the immediate-treatment group and 2.91 kg in the control group (adjusted mean difference, -0.04 kg; 95% CI, -0.09 to 0.02). No between-group differences were observed with respect to serious adverse events associated with screening and treatment. Conclusions Immediate treatment of gestational diabetes before 20 weeks' gestation led to a modestly lower incidence of a composite of adverse neonatal outcomes than no immediate treatment; no material differences were observed for pregnancy-related hypertension or neonatal lean body mass. ? 2023 Massachusetts Medical Society.
ISSN: 00284793 (ISSN)
Digital object identifier: 10.1056/NEJMoa2214956
URI: https://swslhd.intersearch.com.au/swslhdjspui/handle/1/9644
Department: Bankstown-Lidcombe Hospital, Department of Diabetes & Endocrinology
Appears in Collections:Bankstown-Lidcombe Hospital
Liverpool Hospital

Files in This Item:
There are no files associated with this item.


Items in Prosentient are protected by copyright, with all rights reserved, unless otherwise indicated.

Google Media

Google ScholarTM

Who's citing